Literature DB >> 18377756

Open versus endovascular repair of abdominal aortic aneurysm: a survey of Canadian vascular surgeons.

Tara M Mastracci1, Catherine M Clase, Philip J Devereaux, Claudio S Cinà.   

Abstract

OBJECTIVE: The aim of this survey was to determine Canadian vascular surgeons' experience with elective endovascular aortic repair (EVAR) and traditional open repair and their interest in participating in an expertise- based randomized controlled trial (RCT) as opposed to a conventional RCT comparing these 2 procedures.
METHODS: A single-page questionnaire was developed and sent by fax, email or post to all vascular surgeons in Canada. Nonresponders were recontacted on 2 additional occasions to improve the response rate. The questionnaire had 2 sections. The first inquired about current and past practice patterns, including experience in both open and endovascular techniques. The second investigated the surgeons' belief in the value of open as opposed to endovascular repair and the value of expertise-based RCT methodology; it also canvassed their interest in participating in a future trial. Definitions of expertise in open and endovascular repair were drawn from the published literature. Criteria to determine the feasibility of conducting an expertise-based RCT were established a priori.
RESULTS: The questionnaire was sent to 259 surgeons who appeared in multiple vascular surgery databases, and the overall response rate was 56% (95% confidence interval [CI] 50%-62%). The mean career experience was 406 cases (standard deviation [SD] 359) for conventional open abdominal aortic aneurysm (AAA) repair and 24 cases (SD 48) for endovascular repair. Of the responding surgeons, 51% (95% CI 41%-60%) ranked conventional open repair as "probably superior." Respondents were equally interested in participating in an RCT using either expertise-based methodology (54%, 95% CI 44%-63%) or conventional design (51%, 95% CI 41%-60%).
CONCLUSION: Uncertainty exists among vascular surgeons in Canada as to the role of endovascular surgery in the repair of AAA. A national RCT comparing open with endovascular repair in the elective setting is potentially feasible with either expertise-based or conventional design. Increases in the number of surgeons who are willing to participate and have expertise in EVAR, in addition to high recruitment rates among eligible patients, will be necessary to make such a trial feasible in Canada.

Entities:  

Mesh:

Year:  2008        PMID: 18377756      PMCID: PMC2386348     

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  34 in total

Review 1.  Need for expertise based randomised controlled trials.

Authors:  P J Devereaux; Mohit Bhandari; Mike Clarke; Victor M Montori; Deborah J Cook; Salim Yusuf; David L Sackett; Claudio S Cinà; S D Walter; Brian Haynes; Holger J Schünemann; Geoffrey R Norman; Gordon H Guyatt
Journal:  BMJ       Date:  2005-01-08

2.  Short-term (30-day) outcome of endovascular treatment of abdominal aortic aneurism: results from the prospective Registry of Endovascular Treatment of Abdominal Aortic Aneurism (RETA).

Authors:  S M Thomas; P A Gaines; J D Beard
Journal:  Eur J Vasc Endovasc Surg       Date:  2001-01       Impact factor: 7.069

3.  Two decades of abdominal aortic aneurysm repair: have we made any progress?

Authors:  J A Heller; A Weinberg; R Arons; K V Krishnasastry; R T Lyon; J S Deitch; A H Schulick; H L Bush; K C Kent
Journal:  J Vasc Surg       Date:  2000-12       Impact factor: 4.268

4.  Response rates to mail surveys published in medical journals.

Authors:  D A Asch; M K Jedrziewski; N A Christakis
Journal:  J Clin Epidemiol       Date:  1997-10       Impact factor: 6.437

5.  A cumulative analysis of an individual surgeon's early experience with elective open abdominal aortic aneurysm repair.

Authors:  Thomas L Forbes
Journal:  Am J Surg       Date:  2005-04       Impact factor: 2.565

6.  Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial.

Authors: 
Journal:  Lancet       Date:  2005 Jun 25-Jul 1       Impact factor: 79.321

7.  Developing measures of surgeons' equipoise to assess the feasibility of randomized controlled trials in vascular surgery.

Authors:  Jane Young; James Harrison; Geoffrey White; James May; Michael Solomon
Journal:  Surgery       Date:  2004-11       Impact factor: 3.982

8.  Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms.

Authors:  Jan D Blankensteijn; Sjors E C A de Jong; Monique Prinssen; Arie C van der Ham; Jaap Buth; Steven M M van Sterkenburg; Hence J M Verhagen; Erik Buskens; Diederick E Grobbee
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

9.  Experience in the United States with intact abdominal aortic aneurysm repair.

Authors:  T S Huber; J G Wang; A E Derrow; D A Dame; C K Ozaki; G B Zelenock; T C Flynn; J M Seeger
Journal:  J Vasc Surg       Date:  2001-02       Impact factor: 4.268

10.  Screening for abdominal aortic aneurysms: single centre randomised controlled trial.

Authors:  Jes S Lindholt; Svend Juul; Helge Fasting; Eskild W Henneberg
Journal:  BMJ       Date:  2005-03-09
View more
  3 in total

Review 1.  A systematic review of the use of an expertise-based randomised controlled trial design.

Authors:  Jonathan A Cook; Andrew Elders; Charles Boachie; Ted Bassinga; Cynthia Fraser; Doug G Altman; Isabelle Boutron; Craig R Ramsay; Graeme S MacLennan
Journal:  Trials       Date:  2015-05-30       Impact factor: 2.279

Review 2.  Methodological choices for the clinical development of medical devices.

Authors:  Alain Bernard; Michel Vaneau; Isabelle Fournel; Hubert Galmiche; Patrice Nony; Jean Michel Dubernard
Journal:  Med Devices (Auckl)       Date:  2014-09-23

3.  Surgeons' and methodologists' perceptions of utilising an expertise-based randomised controlled trial design: a qualitative study.

Authors:  Jonathan A Cook; Marion K Campbell; Katie Gillies; Zoë Skea
Journal:  Trials       Date:  2018-09-06       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.